← Back to Search

Muscle Stimulation for Stem Cell Transplant Recovery

N/A
Recruiting
Led By Lindsey J Anderson, PhD
Research Sponsored by VA Office of Research and Development
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Veteran enrolled in MTU at VAPSHCS for planned standard of care autologous HCT
Adequate cognitive and language ability to provide consent
Timeline
Screening 3 weeks
Treatment Varies
Follow Up change from before to 1month after transplant
Awards & highlights

Study Summary

This trial is testing a new exercise strategy, neuromuscular electrical stimulation, to see if it can help reduce the long-term effects of cancer treatment, including deconditioning, fatigue, and muscle atrophy.

Who is the study for?
This trial is for Veterans planning to undergo autologous stem cell transplant at VAPSHCS and can consent. It's not for those with active blood clots, untreated bleeding disorders, muscle conditions that forbid electrical stimulation, heart devices, severe liver or kidney disease, previous stem cell transplants, or high baseline muscle soreness.Check my eligibility
What is being tested?
The study tests neuromuscular electrical stimulation (NMES) using the RS-4i Plus Sequential Stimulator to maintain physical function and quality of life after a hematologic stem cell transplant. The goal is to see if NMES can help reduce deconditioning and fatigue from cancer treatment.See study design
What are the potential side effects?
Potential side effects of NMES may include discomfort at the site of electrode placement, skin irritation under the electrodes, muscle soreness similar to what might be felt after exercise, and in rare cases excessive muscle fatigue.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am a veteran enrolled for a stem cell transplant at VAPSHCS.
Select...
I understand and can communicate my decision to participate.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~change from before to 1month after transplant
This trial's timeline: 3 weeks for screening, Varies for treatment, and change from before to 1month after transplant for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Secondary outcome measures
6-Minute Walk Test
Lean Body Mass
Muscle Tissue
+3 more

Trial Design

2Treatment groups
Active Control
Placebo Group
Group I: Active NMESActive Control1 Intervention
asymmetric biphasic waveforms at 71 pulses per second frequency (Hz), 400 s pulse duration, 5:10s on:off time (50% duty cycle), and 1.5s ramp-up time. Participants will be in control of the muscle stimulator devices at all times and will be instructed to perform all sessions in the supine position. Bilateral NMES will be delivered via asymmetric, biphasic using four cutaneous parallel channels delivered simultaneously using 2"x4" or 3"x5" self-adhesive electrodes. For the active NMES group, participants will be encouraged to increase the amplitude to a level of moderate discomfort, such as that experienced during conventional exercise, but not to induce pain. At minimum, the amplitude should induce visible muscle contraction.
Group II: Sham NMESPlacebo Group1 Intervention
The amplitude of the muscle stimulators for the Sham group will be capped at 15 milliamperes so patients will only feel cutaneous sensation without achieving muscle contraction.

Find a Location

Who is running the clinical trial?

VA Office of Research and DevelopmentLead Sponsor
1,614 Previous Clinical Trials
3,305,807 Total Patients Enrolled
Lindsey J Anderson, PhDPrincipal InvestigatorVA Puget Sound Health Care System Seattle Division, Seattle, WA

Media Library

Active NMES 2023 Treatment Timeline for Medical Study. Trial Name: NCT04364256 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Has Active NMES been cleared by the FDA?

"Since this is a Phase 2 trial, there is some evidence backing Active NMES's safety but not its efficacy. The team at Power gave it a score of 2."

Answered by AI

How many people are being involved in this clinical trial?

"The information on clinicaltrials.gov does show that this trial is still open and looking for 46 participants at 1 site. The posting date was 5/14/2021, with the most recent update being 4/21/2022."

Answered by AI

Are researchers still actively recruiting for this trial?

"That's right, the trial is still recruiting patients according to the most recent information on clinicaltrials.gov. The listing was first put up on May 14th, 2021 and edited as recently as April 21st, 2022. They're currently looking for 46 individuals at a single location."

Answered by AI
~15 spots leftby Dec 2025